Matthews FE, Stephan BCM, Robinson L, Jagger C, Barnes LE, Arthur A, et al. A two decade dementia incidence comparison from the cognitive function and ageing studies i and II. Nat Commun. 2016;7.
Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):0587–99.
Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. Dep Heal [Internet]. 2009;60. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_108302.pdf.
Costa N, Wübker A, De Mauléon A, Zwakhalen SMG, Challis D, Leino-Kilpi H, et al. Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study. J Am Med Dir Assoc. 2018;19(1):95.e1–95.e10.
Andrews GJ. Managing challenging behaviour in dementia. BMJ. 2006;332(7544):741 Available from: http://www.bmj.com/content/332/7544/741.abstract.
World Health Organization. Dementia: a public health priority. Dementia [Internet]. 2012;112. Available from: http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdf.
Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry. 2001;16:484–93.
Peklar J, O’Halloran AM, Maidment ID, Henman MC, Kenny RA, Kos M. Sedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years. J Am Med Dir Assoc. 2015;16(4):282–9. Available from: http://www.sciencedirect.com/science/article/pii/S1525861014006720 (accessed 19th Oct 2016).
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83. Available from:. https://doi.org/10.1111/j.1532-5415.2011.03491.x.
Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry. 2012;12(1):1–6. Available from:. https://doi.org/10.1186/1471-244X-12-155.
Van Leeuwen E, Petrovic M, van Driel M, De Sutter A, Vander Stichele R, Declercq T. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;2018(3):CD007726 Available from: http://as.wiley.com/WileyCDA/Brand/id-6.html%0Ahttp://ovidsp.ovid.com/ovidweb.cgi? T=JS&PAGE=reference&D=emexb&NEWS=N&AN=621467374 (accessed 2nd Aug 2018).
Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86.
NHS-England. Care home pharmacists to help cut overmedication and unnecessary hospital stays for frail older patients [Internet]. 2018 [cited 2018 Mar 19]. Available from: https://www.england.nhs.uk/2018/03/care-home-pharmacists-to-help-cut-over-medication-and-unnecessary-hospital-stays-for-frail-older-patients/.
Dementia Action Alliance, Royal Pharmaceutical Society. The Right Prescription : a call to action on the use of antipsychotic drugs for people with dementia [Internet]. 2009. Available from: https://www.rpharms.com/resources/reports/the-right-prescription-a-call-to-action (accessed 15th Mar 2019).
Whitaker R, Fossey J, Ballard C, Orrell M, Moniz-Cook E, Woods RT, et al. Improving well-being and health for people with dementia (WHELD): study protocol for a randomised controlled trial. Trials. 2014;15:284.
Alzheimer S. Dementia UK second edition - overview; 2014.
NICE. Dementia - assessment, management and support for people living with dementia and their carers | Guidance and guidelines | NICE. 2015;(January):1–33. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0792.
Spector A, Revolta C, Orrell M. The impact of staff training on staff outcomes in dementia care: a systematic review. Int J Geriatr Psychiatry. 2016;31(11):1172–87.
Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. PLOS Med. 2018;15(2):e1002500. Available from:. https://doi.org/10.1371/journal.pmed.1002500.
Ballard C, Orrell M, YongZhong S, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health. Am J Psychiatry. 2016;173(3):252–62 Available from: http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15010130.
Leblanc A, Légaré F, Labrecque M, Godin G, Thivierge R, Laurier C, et al. Feasibility of a randomised trial of a continuing medical education program in shared decision-making on the use of antibiotics for acute respiratory infections in primary care: the DECISION+ pilot trial. Implement Sci. 2011;6:5 Available from: hhttps://implementationscience.biomedcentral.com/articles/10.1186/1748-5908-6-5.
Maidment ID, Damery S, Campbell N, Seare N, Fox C, Iliffe S, et al. Medication review plus person-centred care : a feasibility study of a pharmacy-health psychology dual intervention to improve care for people living with dementia. BMC Psychiatry. 2018:1–11 Available from: https://bmcpsychiatry.biomedcentral.com/track/pdf/10.1186/s12888-018-1907-4 (accessed 22nd Oct 2018).
MRC. Developing and evaluating complex interventions: new guidance [Internet]. Vol. 337, Medical Research Council. 2008. Available from: https://www.mrc.ac.uk/documents/pdf/complex-interventions-guidance/ (accessed 28th Oct 2016).
Maidment ID, Shaw RL, Killick K, Damery S, Hilton A, Wilcock J, et al. Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy–health psychology intervention feasibility study. BMJ Open. 2016;6(3) Available from: http://bmjopen.bmj.com/content/6/3/e010279.abstract.
Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol [Internet]. 2012;65(3):301–8. Available from:. https://doi.org/10.1016/j.jclinepi.2011.07.011.
Julious S. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287–91.
Task Force on Medicines Partnership, The National Collaborative Medicines Management Services Programme. Room for review - A guide to medication review: the agenda for patients, practitioners and managers. Med Partnerschip; 2002. p. 48.
Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.
Wood S, Cummings J, Hsu M-A, Barclay T, Wheatley MV, Yarema K, et al. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75–83.
Dolan P. Modelling valuations for EuroQol health states. Med Care. 1997;35:1095–108.
Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia. Heal Technol Assess. 2005;9(10):1.
Molloy D, Alemeyehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry. 1991;148(1):102–5. Available from. https://doi.org/10.1176/ajp.148.1.102.
Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring Mental Health Needs. 2nd ed. London: Royal College of Psychiatrists; 2001.
Lintern T, Woods B, Phair L. Before and after training: a case study of intervention. J Dement Care. 2000;8:15–7.
Maslach C, Jackson S. The measurement of experienced burnout. J Occup Behav. 1981;2:99–113.
Curtis L, Burns A. Unit costs of health and social care; 2016.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
Smith SC, LampingG DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. Development of a new measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med [Internet]. 2007 May 19 [cited 2019 Jan 22];37(05):737. Available from: http://www.journals.cambridge.org/abstract_S0033291706009469.
NICE. Position statement on use of the EQ-5D-5L valuation set for England (updated November 2018) [Internet]. 2018 [cited 2019 Jan 22]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.
Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.
Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Heal. 2012;15(5):708–15. Available from:. https://doi.org/10.1016/j.jval.2012.02.008.
Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R, et al. Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Health Technol Assess (Rockv). 2013;17(5):1–160.
Fossey J. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. Bmj. 2006;332(7544):756–61 Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.38782.575868.7C.
Barber ND, Alldred DP, Raynor DK, Dickinson R, Garfield S, Jesson B, et al. Care homes’ use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. Qual Saf Heal Care [Internet]. 2009;18(5):341–6 Available from: http://qualitysafety.bmj.com/lookup/doi/10.1136/qshc.2009.034231.
NIHR Dissemination Centre. Themed Review - Advancing Care. Research with Care Homes [Internet]. 2017. Available from: http://www.dc.nihr.ac.uk/themed-reviews/advancing-care-themed-review.pdf.
Desborough J, Houghton J, Wood J, Wright D, Holland R, Sach T, et al. Multi-professional clinical medication reviews in care homes for the elderly: study protocol for a randomised controlled trial with cost effectiveness analysis. Trials [Internet]. 2011;12(1):218. Available from: http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-12-218.
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: A randomised double-blind placebo controlled trial. PLoS One [Internet]. 2012;7(5). Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035185.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O’Brien JT, Mountain G, et al. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. PLoS One. 2017;12(6):e0179521..
Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess A J Consult Clin Psychol. 1990;2(3):298–303.
NICE. Guide to the methods of technology appr appraisal aisal 2013 [Internet]. 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 22 Jan 2019).
Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Heal [Internet]. 2018;21(1):49–56. Available from:. https://doi.org/10.1016/j.jval.2017.09.004.
Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873–84.
Alldred D, Kennedy M, Hughes C, Chen T, Miller P. Interventions to optimise prescribing for older people in care homes ( review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. Cochrane Database Syst Rev. 2016;2:68.
Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial- a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess (Rockv). 2013;17(7):1–43.
Basic D, Khoo A, Conforti D, Rowland J, Vrantsidis F, Logiudice D, et al. Rowland universal dementia assessment scale, mini-mental state examination and general practitioner assessment of cognition in a multicultural cohort of community-dwelling older persons with early dementia. Aust Psychol. 2009;44(1):40–53.
Rowland JT, Basic D, Storey JE, Conforti DA. The Rowland Universal Dementia Assessment Scale (RUDAS) and the Folstein MMSE in a multicultural cohort of elderly persons. Int Psychogeriatrics [Internet]. 2006/02/08. 2006;18(1):111–20. Available from: https://www.cambridge.org/core/article/rowland-universal-dementia-assessment-scale-rudas-and-the-folstein-mmse-in-a-multicultural-cohort-of-elderly-persons/44A79D1EB84D9CD31D4F23631AE5D4A3.
NIHR. ENRICH (Enabling Research in Care Homes) [Internet]. 2018 [cited 2018 Mar 1]. Available from: https://enrich.nihr.ac.uk/pages/care-home-staff.